Works by Takeshi Yoshikawa


Results: 124
    1
    2

    High-resolution deep learning reconstruction for coronary CTA: compared efficacy of stenosis evaluation with other methods at in vitro and in vivo studies.

    Published in:
    European Radiology, 2025, v. 35, n. 8, p. 4763, doi. 10.1007/s00330-025-11376-9
    By:
    • Matsuyama, Takahiro;
    • Nagata, Hiroyuki;
    • Ozawa, Yoshiyuki;
    • Ito, Yuya;
    • Kimata, Hirona;
    • Fujii, Kenji;
    • Akino, Naruomi;
    • Ueda, Takahiro;
    • Nomura, Masahiko;
    • Yoshikawa, Takeshi;
    • Takenaka, Daisuke;
    • Kawai, Hideki;
    • Sarai, Masayoshi;
    • Izawa, Hideo;
    • Ohno, Yoshiharu
    Publication type:
    Article
    3

    Pulmonary MRI with ultra-short TE using single- and dual-echo methods: comparison of capability for quantitative differentiation of non- or minimally invasive adenocarcinomas from other lung cancers with that of standard-dose thin-section CT.

    Published in:
    European Radiology, 2024, v. 34, n. 2, p. 1065, doi. 10.1007/s00330-023-10105-4
    By:
    • Ohno, Yoshiharu;
    • Yui, Masao;
    • Yamamoto, Kaori;
    • Ikedo, Masato;
    • Oshima, Yuka;
    • Hamabuchi, Nayu;
    • Hanamatsu, Satomu;
    • Nagata, Hiroyuki;
    • Ueda, Takahiro;
    • Ikeda, Hirotaka;
    • Takenaka, Daisuke;
    • Yoshikawa, Takeshi;
    • Ozawa, Yoshiyuki;
    • Toyama, Hiroshi
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12

    A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.

    Published in:
    European Journal of Haematology, 2002, v. 68, n. 6, p. 354, doi. 10.1034/j.1600-0609.2002.01654.x
    By:
    • Sawada, Michio;
    • Tsurumi, Hisashi;
    • Yamada, Toshiki;
    • Hara, Takeshi;
    • Fukuno, Kenji;
    • Goto, Hideko;
    • Shimizu, Masahito;
    • Kasahara, Senji;
    • Yoshikawa, Takeshi;
    • Kanemura, Nobuhiro;
    • Oyama, Masami;
    • Takami, Tsuyoshi;
    • Moriwaki, Hisataka
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21

    A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.

    Published in:
    Leukemia & Lymphoma, 2012, v. 53, n. 2, p. 247, doi. 10.3109/10428194.2011.606383
    By:
    • Tsurumi, Hisashi;
    • Hara, Takeshi;
    • Goto, Naoe;
    • Kitagawa, Jun-Ichi;
    • Kanemura, Nobuhiro;
    • Yoshikawa, Takeshi;
    • Kasahara, Senji;
    • Goto, Hideko;
    • Fukuno, Kenji;
    • Yamada, Toshiki;
    • Sawada, Michio;
    • Shimizu, Masahito;
    • Takahashi, Takeshi;
    • Takami, Tsuyoshi;
    • Moriwaki, Hisataka
    Publication type:
    Article
    22

    Phase II study of the tetrahydropyranyl adriamycin--cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.

    Published in:
    Leukemia & Lymphoma, 2011, v. 52, n. 4, p. 629, doi. 10.3109/10428194.2011.555024
    By:
    • Kasahara, Senji;
    • Hara, Takeshi;
    • Tsurumi, Hisashi;
    • Goto, Naoe;
    • Kitagawa, Jun-Ichi;
    • Kanemura, Nobuhiro;
    • Yoshikawa, Takeshi;
    • Goto, Hideko;
    • Fukuno, Kenji;
    • Yamada, Toshiki;
    • Sawada, Michio;
    • Takahashi, Takeshi;
    • Takami, Tsuyoshi;
    • Moriwaki, Hisataka
    Publication type:
    Article
    23
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.

    Published in:
    Prostate, 2015, v. 75, n. 16, p. 1821, doi. 10.1002/pros.23088
    By:
    • Goto, Takayuki;
    • Terada, Naoki;
    • Inoue, Takahiro;
    • Kobayashi, Takashi;
    • Nakayama, Kenji;
    • Okada, Yoshiyuki;
    • Yoshikawa, Takeshi;
    • Miyazaki, Yu;
    • Uegaki, Masayuki;
    • Utsunomiya, Noriaki;
    • Makino, Yuki;
    • Sumiyoshi, Shinji;
    • Yamasaki, Toshinari;
    • Kamba, Tomomi;
    • Ogawa, Osamu
    Publication type:
    Article
    41

    R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.

    Published in:
    2018
    By:
    • Hara, Takeshi;
    • Yoshikawa, Takeshi;
    • Goto, Hideko;
    • Sawada, Michio;
    • Yamada, Toshiki;
    • Fukuno, Kenji;
    • Kasahara, Senji;
    • Shibata, Yuhei;
    • Matsumoto, Takuro;
    • Mabuchi, Ryoko;
    • Nakamura, Nobuhiko;
    • Nakamura, Hiroshi;
    • Ninomiya, Soranobu;
    • Kitagawa, Junichi;
    • Kanemura, Nobuhiro;
    • Nannya, Yasuhito;
    • Katsumura, Naoki;
    • Takahashi, Takeshi;
    • Kito, Yusuke;
    • Takami, Tsuyoshi
    Publication type:
    journal article
    42

    FDG-PET/CT imaging of elastofibroma dorsi.

    Published in:
    2011
    By:
    • Onishi, Yumiko;
    • Kitajima, Kazuhiro;
    • Senda, Michio;
    • Sakamoto, Setsu;
    • Suzuki, Kayo;
    • Maeda, Tetsuo;
    • Yoshikawa, Takeshi;
    • Ohno, Yoshiharu;
    • Sugimura, Kazuro
    Publication type:
    journal article
    43

    Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2010, v. 136, n. 1, p. 65, doi. 10.1007/s00432-009-0637-x
    By:
    • Hara, Takeshi;
    • Tsurumi, Hisashi;
    • Goto, Naoe;
    • Kitagawa, Jun-ichi;
    • Kanemura, Nobuhiro;
    • Yoshikawa, Takeshi;
    • Kasahara, Senji;
    • Goto, Hideko;
    • Fukuno, Kenji;
    • Yamada, Toshiki;
    • Sawada, Michio;
    • Yasuda, Ichiro;
    • Katsumura, Naoki;
    • Takahashi, Takeshi;
    • Takami, Tsuyoshi;
    • Moriwaki, Hisataka
    Publication type:
    Article
    44

    Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2009, v. 135, n. 10, p. 1421, doi. 10.1007/s00432-009-0586-4
    By:
    • Hara, Takeshi;
    • Tsurumi, Hisashi;
    • Goto, Naoe;
    • Kanemura, Nobuhiro;
    • Yoshikawa, Takeshi;
    • Kasahara, Senji;
    • Yamada, Toshiki;
    • Sawada, Michio;
    • Goto, Hideko;
    • Fukuno, Kenji;
    • Kitagawa, Jun-ichi;
    • Yasuda, Ichiro;
    • Katsumura, Naoki;
    • Takemura, Masao;
    • Takahashi, Takeshi;
    • Takami, Tsuyoshi;
    • Moriwaki, Hisataka
    Publication type:
    Article
    45

    Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2009, v. 135, n. 1, p. 53, doi. 10.1007/s00432-008-0440-0
    By:
    • Kitagawa, Jun-ichi;
    • Hara, Takeshi;
    • Tsurumi, Hisashi;
    • Goto, Naoe;
    • Kanemura, Nobuhiro;
    • Yoshikawa, Takeshi;
    • Kasahara, Senji;
    • Yamada, Toshiki;
    • Sawada, Michio;
    • Takahashi, Takeshi;
    • Shimizu, Masahito;
    • Takami, Tsuyoshi;
    • Moriwaki, Hisataka
    Publication type:
    Article
    46
    47
    48
    49
    50